BB Biotech AG lowered its holdings in Celgene Corporation (NASDAQ:CELG) by 3.5% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,339,298 shares of the biopharmaceutical company’s stock after selling 120,000 shares during the period. Celgene Corporation makes up 13.6% of BB Biotech AG’s holdings, making the stock its 2nd biggest holding. BB Biotech AG owned approximately 0.43% of Celgene Corporation worth $415,509,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the stock. Motco grew its holdings in Celgene Corporation by 306.9% during the 1st quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 620 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation during the 1st quarter worth approximately $118,000. Oakworth Capital Inc. grew its holdings in Celgene Corporation by 60.9% during the 1st quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 412 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Celgene Corporation by 47.5% during the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares in the last quarter. Finally, Reilly Financial Advisors LLC grew its holdings in Celgene Corporation by 15.3% during the 1st quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 79.43% of the company’s stock.
In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 267,476 shares of company stock worth $35,812,841. 0.95% of the stock is owned by company insiders.
Shares of Celgene Corporation (CELG) traded up 1.02% during midday trading on Friday, reaching $142.04. 5,983,997 shares of the company were exchanged. The firm’s 50 day moving average is $134.97 and its 200-day moving average is $127.46. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.69. The company has a market capitalization of $111.12 billion, a PE ratio of 43.99 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the business earned $1.44 earnings per share. The company’s revenue was up 18.7% on a year-over-year basis. On average, equities analysts forecast that Celgene Corporation will post $7.33 earnings per share for the current fiscal year.
Several research firms have commented on CELG. BTIG Research cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a research report on Thursday, August 10th. Mizuho boosted their price objective on shares of Celgene Corporation from $134.00 to $158.00 and gave the stock a “buy” rating in a research report on Friday. Robert W. Baird restated an “outperform” rating and set a $162.00 price objective on shares of Celgene Corporation in a research report on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $149.34.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.